What is it?
GLP-1 receptor agonist
Peptide Library · checked July 17, 2026
Liraglutide
Liraglutide is an older daily GLP-1 medicine with large randomized trials behind specific products and uses. Older does not mean unproven. It also does not make every unrelated product labeled “liraglutide” equivalent to the drugs that were studied.
EstablishedReplicated relevant human evidence, or approved labeling for the exact use.How labels work →
TL;DR
The lowdown
Four answers first. The source record follows.
What do humans show?
Large randomized weight-management and cardiovascular-outcomes trials
Where does FDA stand?
Approved in specific products and uses; bulk-compounding policy remains a separate question
What is known—and not?
Current FDA-approved labeling contains product-specific contraindications, warnings, precautions, and adverse reactions. Saxenda labeling includes a boxed warning about thyroid C-cell tumors observed in rodents, with unknown human relevance, and discusses gastrointestinal and other risks.
U.S. status · July 17, 2026
Approval, compounding, product, sport.
- FDA approval
- FDA-approved in specific products and indications; FDA proposed against 503B Bulks List inclusion in 2026
- U.S. federal record
- FDA-approved in specific products and indications; FDA proposed against 503B Bulks List inclusion in 2026
- Product identity
- Reviewed named-product record: Saxenda and Victoza; approved generics also exist for specified reference products.
- Sport
- No WADA status recorded in the reviewed source.
This reports the dated federal and sport record. It does not determine whether a particular product or transaction complies with state or federal law, and it is not legal advice.
01
What it is
Liraglutide is a once-daily GLP-1 receptor agonist. Different FDA-approved products containing liraglutide have different indications, labeling, strengths, and reference products.
It is sometimes presented online as merely an obsolete predecessor to weekly GLP-1 medicines. That framing erases a substantial evidence base and can also hide a more basic question: which actual drug product is being discussed?
02
What humans actually show
- Weight management: A 56-week randomized trial enrolled 3,731 adults without diabetes. Mean weight loss was 8.4 kg with liraglutide 3.0 mg and 2.8 kg with placebo, with lifestyle counseling in both groups.
- Cardiovascular outcomes: LEADER randomized 9,340 people with type 2 diabetes and high cardiovascular risk. The primary composite outcome occurred in 13.0% of the liraglutide group and 14.9% of the placebo group.
- Limits of transfer: Those results belong to the populations, products, regimens, and outcomes actually studied. They do not establish the identity, sterility, concentration, or performance of an unrelated product.
03
FDA and U.S. status
FDA-approved liraglutide products include medicines for defined diabetes and chronic weight-management uses. The exact current label should be read for the exact product, because indications and warnings are product-specific.
In April 2026, FDA proposed excluding liraglutide, semaglutide, and tirzepatide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound them from bulk substances. FDA described that as a proposed determination subject to public comment, not a final drug-approval action.
04
Risks and warning limits
Current FDA-approved labeling contains product-specific contraindications, warnings, precautions, and adverse reactions. Saxenda labeling includes a boxed warning about thyroid C-cell tumors observed in rodents, with unknown human relevance, and discusses gastrointestinal and other risks.
Individual risk and product selection require a licensed prescriber. PepCurrent does not provide dosing, sourcing, switching, or personalized treatment advice.
05
What would change this answer
- Final FDA action on the 503B Bulks List proposal
- Label changes and availability of approved generics
- Cardiovascular and long-term weight-management outcomes
- Confusion between ingredient, brand, generic reference product, compounded product, and gray-market vial
06
Sources and records
- Current Saxenda drug labeling on DailyMed
- Pi-Sunyer et al., 2015 — 3,731-person weight-management trial
- Marso et al., 2016 — LEADER cardiovascular-outcomes trial
- FDA 2026 proposal on the 503B Bulks List
Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.
What changed
Added the source-verified Claim Check to the structured claim/source/change registry.
What would change our answer
A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.
Version history · 1 entry
- v1 · 2026-07-17Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: PepCurrent explains public evidence and regulatory records. We do not evaluate individual products, recommend use, name vendors, or provide protocols.